原卟啉IX二甲酯 | 5522-66-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 中文名称: 原卟啉IX二甲酯
• 中文别名: 间卟啉二甲酯
• 英文名称: Protoporphyrin IX dimethyl ester
• 英文别名: methyl 3-[8,13-bis(ethenyl)-18-(3-methoxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoate
• CAS: 5522-66-7；6164-53-0
• 化学式: C₃₆H₃₈N₄O₄
• 分子量: 590.7
• InChiKey: LQBPATQBTSBIIH-UHFFFAOYSA-N

物化性质

• 熔点：
  225-228 °C(lit.)
• 沸点：
  1017.0±65.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

SDS

---

Section 1: Product Identification
Chemical Name: Protoporphyrin IX dimethyl ester
CAS Registry Number: 5522-66-7
Formula: C36H38N4O4
EINECS Number: 226-870-3
Chemical Family: porphine (porphyrin) ligand
Synonym: None

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title Compound 5522-66-7 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: No particular hazard associated with this material.
Primary Routes of Exposure: Ingestion, inhalation
Eye Contact: May cause slight to mild irritation of the eyes.
Skin Contact: May cause slight to mild irritation of the skin.
Inhalation: May be irritating to the nose, mucous membranes and respiratory tract.
Ingestion: No specific information is available on the physiological effects of ingestion.
Acute Health Affects: May be irritating to skin, eyes and respiratory tract.
Chronic Health Affects: No information available on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: no data
Autoignition Temperature: none
Explosion Limits: none
Extinguishing Medium: carbon dioxide, dry powder or foam
If this material is involved in a fire, fire fighters should be equipped with a NIOSH approved, positive pressure
Special Fire Fighting Procedures:
self contained breathing apparatus and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit toxic organic fumes.
Decomposion Products:
Unusual Fire or Explosion Hazards: No unusual fire or explosion hazards.

---

SECTION 6: Accidental Release Measures
Spill and Leak Procedures: Small spills can be mixed with vermiculite or sodium carbonate and swept up.

---

SECTION 7: Handling and Storage
Handling and Storage: Store in a tightly sealed container. Keep away from heat and direct sunlight.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Material may form a fine dust. If possible, handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: purple xtl.
Molecular Weight: 590.73
Melting Point: no data
Boiling Point: no data
Vapor Pressure: not applicable
Specific Gravity: no data
Odor: none
Solubility in Water: insoluble

---

SECTION 10: Stability and Reactivity
Stability: air and moisture stable solid
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: none
Incompatibility: oxidizing agents
Decomposition Products: carbon dioxide, carbon monoxide, nitrogen oxides, and organic fumes

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: No data available
Mutagenic Effects: No data available
Tetratogenic Effects: No data available

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: Listed in the TSCA inventory.
SARA (Title 313): Not reportable under SARA Title 313
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

原卟啉 IX 二甲酯为深紫色粉末状物质，可溶于 DMSO、丙酮和氯仿。

反应信息

• 作为反应物：
  描述：

  原卟啉IX二甲酯 在 钯 作用下， 以 二氯甲烷 为溶剂， 生成 Mesoporphyrin ix dimethyl ester
  参考文献：
  名称：

  Methods for synthesizing metal mesoporphyrins

  摘要：

  实施例描述了合成金属中间体卟啉化合物的方法。在实施例中，可以通过血红素转金属化和随后的氢化锡原卟啉IX来形成金属中间体卟啉化合物。在其他实施例中，合成金属中间体卟啉化合物的方法包括从血红素形成原卟啉甲酯，然后通过金属插入和氢化将原卟啉甲酯中间体转化为金属中间体卟啉化合物。在其他实施例中，可以通过无氢氢化方法从血红素形成mesoporphyrin IX中间体，随后进行金属插入和氢化来形成金属中间体卟啉化合物。在实施例中，合成金属中间体卟啉化合物的方法包括形成mesoporphyrin IX二盐酸盐中间体化合物，并通过金属插入将mesoporphyrin IX中间体转化为金属中间体卟啉化合物。在实施例中，可以直接从血红素形成金属中间体卟啉化合物，而无需隔离任何中间体。

  公开号：

  US09181285B2
• 作为产物：
  描述：

  3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate 、 对甲苯磺酸 、 氨 、 溶剂黄146 、 氯苯 在 氮气 、 乙酸乙酯 、 Sodium sulfate-III 、 甲醇 、 硫酸 、 水 、 二氯甲烷 、 碳酸氢钠 、 crude product 、 silica 、 chloroform methanol 、 1H 作用下， 反应 18.0h， 以yielded protoporphyrin IX dimethyl ester 26 (365 mg, 83.1%) as a dark red solid, m.p. 198-202° C. with an identical 1H NMR spectrum to的产率得到原卟啉IX二甲酯
  参考文献：
  名称：

  PORPHYRIN LINKED METRONIDAZOLE AGAINST GUM DISEASE: PORPHYROMONAS GINGIVALIS

  摘要：

  本发明一般涉及定向分子制剂（TMAs），其针对特定生物体或生物群体及其使用。更具体地说，本发明提供具有定向基团的TMAs，该定向基团包括特定生物体的自然或诱导的营养需求，作为将与基团连接的制剂引导到目标生物体的载体。本发明的TMAs可用于将抗微生物制剂和诊断制剂等分子定向到所选生物体。

  公开号：

  US20090092550A1

文献信息

• Methods for synthesizing metal mesoporphyrins
  申请人：Boucher Christopher P.

  公开号：US08735574B2

  公开（公告）日：2014-05-27

  Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates.

  实施例描述了合成金属中间体卟啉化合物的方法。在实施例中，可以通过血红素转金属作用和随后的锡原卟啉IX的氢化来形成金属中间体卟啉化合物。在其他实施例中，合成金属中间体卟啉化合物的方法包括从血红素形成原卟啉甲酯，通过金属插入和氢化将原卟啉甲酯中间体转化为金属中间体卟啉化合物。在其他实施例中，可以通过无氢氢化方法从血红素形成中间体卟啉IX，然后进行金属插入和氢化来形成金属中间体卟啉化合物。在实施例中，合成金属中间体卟啉化合物的方法包括形成中间体卟啉IX二盐酸盐化合物，并通过金属插入将中间体卟啉IX转化为金属中间体卟啉化合物。在实施例中，可以直接从血红素形成金属中间体卟啉化合物，而无需隔离任何中间体。
• METHODS FOR SYNTHESIZING METAL MESOPORPHYRINS
  申请人：INFACARE PHARMACEUTICAL CORPORATION

  公开号：US20140228560A1

  公开（公告）日：2014-08-14

  Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates.

  实施例描述了合成金属介孔卟啉化合物的方法。在实施例中，金属介孔卟啉化合物可以通过血红素跨金属和随后的氢化锡原卟啉IX形成金属介孔卟啉。在其他实施例中，合成金属介孔卟啉化合物的方法包括从血红素形成原卟啉甲酯，通过金属插入和氢化将原卟啉甲酯中间体转化为金属介孔卟啉化合物。在其他实施例中，金属介孔卟啉化合物可以通过无氢氢化方法从血红素形成介孔卟啉IX中间体，然后进行金属插入和氢化来形成。在实施例中，合成金属介孔卟啉化合物的方法包括形成介孔卟啉IX二盐酸盐中间化合物，并通过金属插入将介孔卟啉IX中间体转化为金属介孔卟啉化合物。在实施例中，金属介孔卟啉化合物可以直接从血红素形成，无需隔离任何中间体。
• PORPHYRIN LINKED METRONIDAZOLE AGAINST GUM DISEASE: PORPHYROMONAS GINGIVALIS
  申请人：Crossley Max

  公开号：US20090092550A1

  公开（公告）日：2009-04-09

  The present invention relates generally to targeted molecular agents (TMAs) directed to a particular organism or group of organisms and uses thereof. More particularly, the present invention provides TMAs having a targeting moiety which comprises a natural or induced auxotrophic requirement of the particular organism as a vehicle for directing an agent linked to the moiety to be delivered to the target organism. The TMAs of the present invention are useful for targeting molecules such as antimicrobial agents and diagnostic agents to selected organisms.

  本发明一般涉及定向分子制剂（TMAs），其针对特定生物体或生物群体及其使用。更具体地说，本发明提供具有定向基团的TMAs，该定向基团包括特定生物体的自然或诱导的营养需求，作为将与基团连接的制剂引导到目标生物体的载体。本发明的TMAs可用于将抗微生物制剂和诊断制剂等分子定向到所选生物体。